182 related articles for article (PubMed ID: 21436072)
1. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.
Flick MJ; Chauhan AK; Frederick M; Talmage KE; Kombrinck KW; Miller W; Mullins ES; Palumbo JS; Zheng X; Esmon NL; Esmon CT; Thornton S; Becker A; Pelc LA; Di Cera E; Wagner DD; Degen JL
Blood; 2011 Jun; 117(23):6326-37. PubMed ID: 21436072
[TBL] [Abstract][Full Text] [Related]
2. A knockout for knockin.
Mosnier LO
Blood; 2011 Jun; 117(23):6058-60. PubMed ID: 21659551
[No Abstract] [Full Text] [Related]
3. How Thrombomodulin Enables W215A/E217A Thrombin to Cleave Protein C but Not Fibrinogen.
Peacock RB; McGrann T; Zaragoza S; Komives EA
Biochemistry; 2022 Jan; 61(2):77-84. PubMed ID: 34978431
[TBL] [Abstract][Full Text] [Related]
4. Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.
Shaw MA; Kombrinck KW; McElhinney KE; Sweet DR; Flick MJ; Palumbo JS; Cheng M; Esmon NL; Esmon CT; Brill A; Wagner DD; Degen JL; Mullins ES
Blood; 2016 Aug; 128(5):721-31. PubMed ID: 27252233
[TBL] [Abstract][Full Text] [Related]
5. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.
Mullins ES; Kombrinck KW; Talmage KE; Shaw MA; Witte DP; Ullman JM; Degen SJ; Sun W; Flick MJ; Degen JL
Blood; 2009 Jan; 113(3):696-704. PubMed ID: 18927430
[TBL] [Abstract][Full Text] [Related]
6. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.
Gruber A; Cantwell AM; Di Cera E; Hanson SR
J Biol Chem; 2002 Aug; 277(31):27581-4. PubMed ID: 12070133
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A.
Gandhi PS; Page MJ; Chen Z; Bush-Pelc L; Di Cera E
J Biol Chem; 2009 Sep; 284(36):24098-105. PubMed ID: 19586901
[TBL] [Abstract][Full Text] [Related]
8. Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.
Rühl H; Berens C; Winterhagen FI; Reda S; Müller J; Oldenburg J; Pötzsch B
Circ Res; 2019 Aug; 125(5):523-534. PubMed ID: 31314700
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin deficiency results in embryonic and neonatal lethality in mice.
Sun WY; Witte DP; Degen JL; Colbert MC; Burkart MC; Holmbäck K; Xiao Q; Bugge TH; Degen SJ
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7597-602. PubMed ID: 9636195
[TBL] [Abstract][Full Text] [Related]
10. A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
Shim K; Zhu H; Westfield LA; Sadler JE
Blood; 2004 Jul; 104(2):415-9. PubMed ID: 15039280
[TBL] [Abstract][Full Text] [Related]
11. The Dual Regulatory Role of Amino Acids Leu480 and Gln481 of Prothrombin.
Wiencek JR; Hirbawi J; Yee VC; Kalafatis M
J Biol Chem; 2016 Jan; 291(4):1565-1581. PubMed ID: 26601957
[TBL] [Abstract][Full Text] [Related]
12. Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance.
Takagi Y; Murata M; Kozuka T; Nakata Y; Hasebe R; Tamura S; Takagi A; Matsushita T; Saito H; Kojima T
Thromb Haemost; 2016 Nov; 116(6):1022-1031. PubMed ID: 27604259
[TBL] [Abstract][Full Text] [Related]
13. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.
Yegneswaran S; Nguyen PM; Gale AJ; Griffin JH
Thromb Haemost; 2009 Jan; 101(1):55-61. PubMed ID: 19132189
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation.
Takagi Y; Kato I; Ando Y; Nakamura Y; Murata M; Takagi A; Murate T; Kojima T
Thromb Res; 2014 Oct; 134(4):914-7. PubMed ID: 25149909
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
Ding Q; Yang L; Zhao X; Wu W; Wang X; Rezaie AR
Thromb Haemost; 2017 Feb; 117(3):479-490. PubMed ID: 27975099
[TBL] [Abstract][Full Text] [Related]
16. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype.
Akhavan S; De Cristofaro R; Peyvandi F; Lavoretano S; Landolfi R; Mannucci PM
Blood; 2002 Aug; 100(4):1347-53. PubMed ID: 12149217
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the anticoagulant profile of meizothrombin.
Stojanovski BM; Pelc LA; Zuo X; Pozzi N; Cera ED
Biomol Concepts; 2018 Dec; 9(1):169-175. PubMed ID: 30864392
[TBL] [Abstract][Full Text] [Related]
18. Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis.
Vicente CP; Weiler H; Di Cera E; Tollefsen DM
Thromb Res; 2012 Oct; 130(4):646-8. PubMed ID: 22178578
[TBL] [Abstract][Full Text] [Related]
19. Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.
Huang X; Swanson R; Kroh HK; Bock PE
J Biol Chem; 2019 May; 294(19):7644-7657. PubMed ID: 30918026
[TBL] [Abstract][Full Text] [Related]
20. Gly74Ser mutation in protein C causes thrombosis due to a defect in protein S-dependent anticoagulant function.
Chen C; Yang L; Villoutreix BO; Wang X; Ding Q; Rezaie AR
Thromb Haemost; 2017 Jun; 117(7):1358-1369. PubMed ID: 28405673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
